The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
Clinical trial NCT05011669 · COMPLETED
Trial details
- NCT number
- NCT05011669
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-16
- Primary completion
- 2023-04-16
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.